Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Homo sapiens (Human) Polyclonal antibody

HGPRT; HGPRTase; HPRT; Lesch-Nyhan Syndrome; Hypoxanthine-guanine phosphoribosyltransferase

  • Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Packages (Simulation)
  • Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Packages (Simulation)
  • Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Used in DAB staining on fromalin fixed paraffin- embedded kidney tissue
  • PAA717Hu01.jpg WB Image
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

SPECIFITY

The antibody is a rabbit polyclonal antibody raised against HPRT1. It has been selected for its ability to recognize HPRT1 in immunohistochemical staining and western blotting.

USAGE

Western blotting: 1:50-400
Immunocytochemistry in formalin fixed cells: 1:50-500
Immunohistochemistry in formalin fixed frozen section: 1:50-500
Immunohistochemistry in paraffin section: 1:10-100
Enzyme-linked Immunosorbent Assay: 1:100-1:5000
Optimal working dilutions must be determined by end user.

STORAGE

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for one year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Reference

  • J Crohns Colitis.Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.Pubmed:25518051
  • J CrohnsResponse to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of tenascin CPubMed: 25518051